Flagship folds three biotechs into Etcelera to predict drug behaviour. Flagship Pioneering has merged Cellarity, Etiome and Empress Therapeutics into a single company betting that better causal biology data will rescue the one in two drugs that fail in Phase 2. Published: October 29, 2026 Flagship Pioneering has merged the technology platforms of three of its own portfolio companies into a single drug discovery business called Etcelera, uniting Cellarity, Etiome and Empress Therapeutics under one roof. The Cambridge, Massachusetts venture engine said the combined company will chase what it calls causal intelligence in human biology: the ability to work out what actually drives a disease and to predict how a medicine will behave in patients before anyone runs a trial. Why a merger instead of a new startup. Each of the three units approached the same problem from a different angle. Cellarity reads cell behaviour rather than single molecular targets, Etiome studies the early drivers of disease, and Empress Therapeutics works on small molecules derived from microbial chemistry. Stacked together with Flagship's internal AI models, the argument is that three partial views of biology add up to something closer to cause and effect. Ad Rawcliffe, a veteran company builder, takes over as CEO. Alec Reynolds, a Flagship senior partner, will chair the board. Small molecules first, then data services. Etcelera launches with programs already drawn from the three predecessor platforms in hematology, including myelofibrosis and essential thrombocythemia, in metabolism including partnered MASH work, and in immunology. The company expects to sell high-impact partnerships and data services alongside its own pipeline, a model Flagship has used before to keep platform companies funded between milestones. Flagship, founded in 2000, has originated more than 100 scientific ventures and reports about $14B under management. Noubar Afeyan, its founder and CEO, co-founded Etcelera.

AN2 Therapeutics names Cameron Trenor chief medical officer as pipeline advances. August 24, 2026 Cameron Trenor AN2 Therapeutics has appointed Cameron Trenor, M.D., as chief medical officer, adding an executive with more than 20 years of clinical and translational development experience as the company advances a pipeline spanning hematologic diseases, infectious diseases and oncology. The clinical-stage biopharmaceutical company, which develops small-molecule therapeutics from its boron chemistry platform, expects three Phase 2 studies to be active in 2026. Trenor will bring experience moving drug candidates from translational research through clinical development, regulatory interactions and commercialization planning. He succeeds the clinical leadership provided over the past two years by AN2 co-founder and Senior Scientific Advisor George H. Talbot, M.D. Talbot will assist with the transition and continue serving the company as a strategic advisor. "Cameron's extensive experience building and leading clinical organizations, advancing innovative therapies through development, and engaging with regulators, investigators and patients will be invaluable as we continue to advance our pipeline," said Eric Easom, co-founder, president and CEO of AN2 Therapeutics. Trenor most recently served as chief medical officer of Cellarity, where he established the company's medical organization as it transitioned into a clinical-stage biotechnology business. He oversaw development of Cellarity's lead program, including its first Investigational New Drug application and the initiation of a global first-in-human clinical study. Before Cellarity, Trenor was executive medical director at Forma Therapeutics, which was acquired by Novo Nordisk. At Forma, he led global clinical development activities for etavopivat across multiple indications and supported the program's progression from early clinical development into Phase 3. Earlier in his career, Trenor led clinical and translational programs focused on hematology and rare diseases at the Novartis Institutes for BioMedical Research. His experience also extends across oncology, immunology and metabolic disorders, giving AN2 clinical-development expertise across several areas relevant to its current and emerging programs. Trenor remains a practicing pediatric hematologist-oncologist at Boston Children's Hospital and has authored approximately 60 peer-reviewed research publications. He is board-certified in pediatric hematology-oncology. He earned a bachelor's degree in biology from Tufts University and his medical degree from the University of Tennessee College of Medicine. He also received a Master of Medical Sciences degree in Clinical Investigation from Harvard Medical School and completed residency and fellowship training through Boston Children's Hospital, Boston Medical Center and Dana-Farber Cancer Institute. The appointment comes as AN2 moves multiple programs toward or through clinical development. The company said its pipeline includes three Phase 2 studies expected to be active during 2026, along with two preclinical oncology candidates. It also has advanced research programs targeting oncology, bone disorders and infectious diseases. For AN2, the addition of a chief medical officer with experience establishing clinical organizations and managing global development programs adds infrastructure as the company's portfolio becomes more clinically active. The role encompasses a stage of drug development where trial execution, regulatory coordination and development prioritization become increasingly important as multiple programs progress simultaneously. AN2 develops its small-molecule drug candidates using a boron chemistry platform. The company is focused on applying that chemistry across therapeutic areas where it believes new compounds can address unmet medical needs. Easom also credited Talbot for his role in overseeing AN2's clinical programs and his contributions since the company's formation. His continued involvement as an advisor provides continuity as Trenor assumes responsibility for the clinical organization and AN2 works to execute its expanding development agenda.

Cellarity announces two oral presentations during the 67th American Society of Hematology Annual Meeting. * Oral Presentation during the emerging targets session on CLY-124, a clinical stage, first-in-class DCN1 inhibitor designed for sickle cell disease * Second oral presentation during the novel therapeutics session illustrating Cellarity's approach to selectively targeting JAK2V617F in patients with myelofibrosis SOMERVILLE, Mass.-(BUSINESS WIRE)-Cellarity, a clinical-stage, biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced acceptance of two oral presentations on its sickle cell disease (SCD) and myelofibrosis programs during the 67th American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 in Orlando, Florida. "Cellarity's approach to discovering and developing transformational therapies applies an advanced transcriptomics and AI-powered platform to discover, characterize and target cellular pathways that contribute to disease. The data we're presenting at ASH this year illustrate the profound potential for impact of this approach in sickle cell disease and myelofibrosis - two challenging diseases with high unmet medical need," said Cameron Trenor, M.D., Chief Medical Officer of Cellarity. "We are excited to unveil differentiating data for our lead asset, CLY-124, which is currently under evaluation in a Phase 1 trial, as well as emerging insights on novel, highly selective small molecules designed with disease modifying potential to reverse JAK2-aberrant cell behavior that drives myelofibrosis." Oral Presentation Details Oral Presentation: Identification of small molecules that selectively target JAK2V617F driven cytokine-independent megakaryopoiesis by leveraging single cell RNA sequencing maps of myelofibrosis patient samples and a deep learning framework (Pub 389) Session 802: Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies? Time and location: December 6, 5:00 - 5:15 PM, OCCC - W331 About Cellarity Founded by Flagship Pioneering in 2019, Cellarity is pioneering a fundamentally new approach to drug discovery that corrects whole cell-state dysfunction to solve complex diseases. The Company's proprietary drug discovery platform leverages advanced transcriptomics to comprehensively understand gene networks and applies the power of dynamic AI modeling to predict and design oral Cell State-Correcting therapeutics that can precisely regulate genetic switch mechanisms to restore proper cell function. The Company's lead asset, CLY-124, is designed to treat sickle cell disease through a novel globin-switching mechanism and is under evaluation in a Phase 1 clinical study. Additional candidates designed by the platform are advancing for indications in hematology and immunology, and Cellarity has an active collaboration with Novo Nordisk targeting metabolic dysfunction-associated steatohepatitis (MASH). For more information visit www.cellarity.com.